Caris Life Sciences Inc., a leading AI-driven company in precision medicine, announced the validation and extension of findings on tumor-infiltrating clonal hematopoiesis (TI-CH) through a study published in the New England Journal of Medicine. The study analyzed 3,255 matched tumor-blood NGS samples from Caris' extensive clinico-genomic database, focusing on patients with late-stage cancer. It confirmed the prevalence of TI-CH across solid tumors, with the highest incidence found in non-small cell lung cancer, affecting approximately 23% of patients. The study also highlighted that patients with TI-CH have a 30% higher risk of death compared to those without TI-CH. These findings underscore the critical role of clonal hematopoietic mutations in precision oncology, aiming to improve patient outcomes. Results from the study have already been presented and are available for viewing on the Caris Life Sciences website.